title: [Alpha blockers, TUS-P and TUR-P in the treatment of benign prostatic hypertrophy. A comparison using multivariate statistical analysis].
abstract: To evaluate the effectiveness of Alpha-blockers, TUI-P and TUR-P in the treatment of obstruction due to BPH, 50 patients, never before treated, were considered. Fifteen were treated with alfuzosin chlorhydrate 7.5 mg/day for four months, 15 were submitted to TUI-P and 20 to TUR-P. In all patients linear purr was carried out before treatment and was repeated from 60 to 90 days after intervention in surgical patients and during the fourth month of treatment in patients treated with alfuzosin. The data obtained were analyzed with the T-test both for dependent and independent samples. The results show that Alpha-blocker contain an increase in maximal flow, without decreasing bladder voiding pressures. On the contrary TUI-P and TUR-P, besides the increase in maximal flow obtain a significant reduction of bladder pressures. The conclusions are the following: maximal flow alone is not a sufficient parameter to evaluate the work of the bladder, the entity of the obstruction and the effectiveness of the therapy. The treatment with Alpha-blockers is unable to reduce the obstruction due to BPH. TUI-P and TUR-P realize an effective deobstruction. Under the same deobstructing effect TUR-P assures a better voiding performance by obtaining higher flow values.
authors.affiliation: Unità Operativa di Urologia, Ospedale di Busto Arsizio, Va.
authors.forename: S
authors.initials: S
authors.lastname: Chisena
authors.forename: A
authors.initials: A
authors.lastname: Mandressi
authors.forename: A
authors.initials: A
authors.lastname: Zaroli
authors.forename: M
authors.initials: M
authors.lastname: Belloni
authors.forename: D
authors.initials: D
authors.lastname: Antonelli
authors.forename: S
authors.initials: S
authors.lastname: Bernasconi
authors.forename: C
authors.initials: C
authors.lastname: Buizza
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014563:Urodynamics
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin; D017430:Prostate-Specific Antigen